VA Utilizes IBM’s Watson AI in Cancer Treatment
By Debbie Gregory.
The Department of Veteran Affairs (VA) and IBM Watson Health have announced an extension of their partnership to bring artificial intelligence and genomic analytics to cancer care.
Watson’s AI is used to identify the specific cancer genome present in a patient and using that knowledge to tailor treatment. The VA’s precision oncology program has treated more than 2,700 veterans, primarily with stage 4 cancer who are eligible for alternative treatment options.
The computer system was initially developed to answer questions on the quiz show Jeopardy! and, in 2011, Watson competed against legendary champions Brad Rutter and Ken Jennings, beating out the top competitors.
But Watson’s mission in the VA is meant to serve a much higher purpose.
“Our mission with VA’s precision oncology program is to bring the most advanced treatment opportunities to Veterans, in hopes of giving our nation’s heroes better treatments through these breakthroughs,” said Acting VA Secretary Peter O’Rourke.
Watson for Oncology has received some less-than-flattering press; last September, the health care news site Stat News found that “the supercomputer isn’t living up to the lofty expectations IBM created for it.”
The supercomputer came under fire for providing incorrect and ‘unsafe’ healthcare treatment advice to cancer patients. In one example, a patient was recommended a drug that could lead to severe or fatal hemorrhage while he was already dealing with severe bleeding due to his condition.
“It is still struggling with the basic step of learning about different forms of cancer,” Stat reported. “Only a few dozen hospitals have adopted the system, which is a long way from IBM’s goal of establishing dominance in a multibillion-dollar market.”
The VA treats 3.5 percent of the nation’s cancer patients, the largest group of cancer patients within any one healthcare entity. The department isn’t paying for Watson, with the latest extension in the partnership still part of a free trial.